Dizal Pharmaceutical's sunvozertinib (Zegfrovy) received accelerated approval from the FDA for treating adults with metastatic non-small-cell lung cancer harboring EGFR exon 20 insertion mutations post platinum chemotherapy. This oral FGFR2/3 inhibitor was granted priority review and breakthrough therapy designation. Regulatory approval was also secured for the Thermo Fisher Oncomine Dx Express Test as a companion diagnostic to identify eligible patients. Dizal now enters direct competition with Johnson & Johnson’s Rybrevant in this rare genetic subset of lung cancer.